Sugi Predict

Sugi Predict / Compounds / SCHEMBL4008565

SCHEMBL4008565

SCHEMBL4008565

CC(C)(C)OC(=O)N1CCCC(OS(C)(=O)=O)CC1

nearest known ligand 0.54

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.54
▸ GPR119 Q8TDV5 13/20 0.49
▸ EPHX1 P07099 1/20 0.48
▸ RECQL P46063 1/20 0.45
▸ MEN1 O00255 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ USP2 O75604 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29981135 1.00 HPGD (0.54) HPGDGPR119EPHX1RECQLMEN1
SCHEMBL57106 0.94 GPR119 (0.53) HPGDGPR119EPHX1RECQLUSP2
SCHEMBL31496241 0.89 GPR119 (0.61) HPGDGPR119EPHX1RECQLUSP2
SCHEMBL731800 0.89 MEN1 (0.49) HPGDGPR119EPHX1MEN1ALDH1A1
SCHEMBL215720 0.89 MEN1 (0.49) HPGDGPR119EPHX1MEN1ALDH1A1
SCHEMBL215721 0.89 MEN1 (0.49) HPGDGPR119EPHX1MEN1ALDH1A1
SCHEMBL13060395 0.86 HPGD (0.66) HPGDGPR119RECQLMAPT
SCHEMBL31565588 0.86 GPR119 (0.55) HPGDGPR119
SCHEMBL20294708 0.85 GPR119 (0.53) HPGDGPR119EPHX1RECQL
SCHEMBL66145 0.85 GPR119 (0.48) HPGDGPR119EPHX1RECQLMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4514794-B1 FGFR2 INHIBITOR COMPOUNDS LILLY CO ELI (US) 2026-03-25 — — EP disclosed
EP-4638454-A1 SUBSTITUTED IMIDAZO-BASED COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK3 Celgene Corporation (US) 2025-10-29 — — EP disclosed
WO-2025202889-A1 HER2 MUTATION INHIBITORS ARRAY BIOPHARMA INC. (US) 2025-10-02 — — WO disclosed
US-20250263409-A1 FGFR2 INHIBITOR COMPOUNDS ELI LILLY AND COMPANY 2025-08-21 — — US disclosed
US-20250115591-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LTD (IE) 2025-04-10 — — US disclosed
US-20250115598-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2025-04-10 — — US disclosed
US-20250090524-A1 BTK INHIBITORS BIOGEN MA INC. 2025-03-20 — — US disclosed
US-20250059188-A1 ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2025-02-20 — — US disclosed
US-20250019378-A1 PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS HALIA THERAPEUTICS INC (US) 2025-01-16 — — US disclosed
EP-4452978-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2024-10-30 — — EP disclosed
US-20140171418-A1 Antibacterial homopiperidinyl substituted 3,4 dihydro 1H[1,8]naphthyridinones JANSSEN SCIENCES IRELAND UC (IE) 2014-06-19 — — US disclosed
US-20140171418-A1 Antibacterial homopiperidinyl substituted 3,4 dihydro 1H[1,8]naphthyridinones JANSSEN SCIENCES IRELAND UC (IE) 2014-06-19 — — US disclosed
US-8481524-B2 c-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-07-09 — — US disclosed
EP-1924572-B1 REGIOSELECTIVE PROCESS FOR PREPARING BENZIMIDAZOLE THIOPHENES SMITHKLINE BEECHAM CORP (US) 2009-12-30 — — EP disclosed
US-7618985-B2 Isoquinoline derivatives N.V. ORGANON (NL) 2009-11-17 — — US disclosed
EP-1963304-B1 ISOQUINOLINE DERIVATIVES ORGANON NV (NL) 2009-06-24 — — EP disclosed
US-20080249301-A1 Regioselective Process for Preparing Benzimidazole Thiophenes SMITHKLINE BEECHAM CORPORATION 2008-10-09 — — US disclosed
US-20080249301-A1 Regioselective Process for Preparing Benzimidazole Thiophenes SMITHKLINE BEECHAM CORPORATION 2008-10-09 — — US disclosed
US-20080249301-A1 Regioselective Process for Preparing Benzimidazole Thiophenes SMITHKLINE BEECHAM CORPORATION 2008-10-09 — — US disclosed
US-20070135479-A1 Isoquinoline derivatives N.V. ORGANON (NL) 2007-06-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135479-A1 Isoquinoline derivatives ROCK1, ROCK2, RHOA HPGD 1597/4885GPR119 804/4885EPHX1 1274/4885
US-20140171418-A1 Antibacterial homopiperidinyl substituted 3,4 dihydro 1H[1,8]naphthyridinones NQO2, ALPI, DHPS HPGD 56/4885GPR119 4196/4885EPHX1 1375/4885
US-20250019378-A1 PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS TYRO3, TH, TYR HPGD 3051/4885GPR119 1017/4885EPHX1 2820/4885
US-20250090524-A1 BTK INHIBITORS BTK, SYK, LYN HPGD 3898/4885GPR119 3235/4885EPHX1 3433/4885
US-20250115598-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS MLKL, CASP1, CASP9 HPGD 1524/4885GPR119 2316/4885EPHX1 1126/4885
US-20250263409-A1 FGFR2 INHIBITOR COMPOUNDS FGFR2, FGFR1, FGFR3 HPGD 4734/4885GPR119 582/4885EPHX1 2399/4885
US-20250115591-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS NLRP3, NOD1, NLRP1 HPGD 2900/4885GPR119 23/4885EPHX1 1846/4885
US-20080249301-A1 Regioselective Process for Preparing Benzimidazole Thiophenes CYP3A4, CYP2C19, CYP2B6 HPGD 1557/4885GPR119 3158/4885EPHX1 2764/4885
US-20250059188-A1 ARYLSULPHONAMIDE COMPOUNDS MLKL, CASP1, CASP9 HPGD 1256/4885GPR119 1420/4885EPHX1 1942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.